knowledge -WSS

knowledge

author：explore 2025-08-26 02:48:27 - browse：1

U.S. legislation that would sever ties with Chinese drugmakers would jeopardize the drug supply for millions of American patients if it’s passed, the biotechnology industry’s main trade group has told Congress.

Congress is considering legislation, called the BIOSECURE Act, that would make it difficult for Chinese contract development and manufacturing organizations to do business with biotechnology companies that work with the U.S. federal government. Biotechs hire Chinese CDMOs, as they’re often called, for services that include product manufacturing, development, formulation, packaging, and distribution.

The BIOSECURE Act would stop the federal government from contracting with, or providing grants to, companies that do business with so-called Chinese “companies of concern.” The impact of the legislation would depend in large part on who is in the White House. The White House’s Office of Management and Budget would determine which companies are blacklisted, but a handful of specific companies would automatically go on that list, including the biotech giant WuXi AppTec.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： What the cancer research community can learn from the Covid response

hotspot

WSS

Pregnancy ages women, but effects reverse after delivery

What the cancer research community can learn from the Covid response

6 surprising facts about sugar

Diabetes management: Digital health tools fall short, study says

CRISPR technology availability, affordability needs to be expanded

What the cancer research community can learn from the Covid response

hotspot

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

leisure time

Psychedelics group wrestles with new pharma identity

Mega Millions jackpot rises to record $1.55 billion for Tuesday's drawing

In Memoriam: Notable people who died in 2023

'Patient friction coefficient' can gauge a clinical trial's patient burden

Psychedelics group wrestles with new pharma identity

Treeline, Josh Bilenker's next biotech, is cloaked in mystery

In Memoriam: Notable people who died in 2023

ER docs worry over extreme heat as a 'mass casualty event'

ChatGPT in medicine: STAT answers readers' burning questions

With Wegovy coverage, Medicare patients may face high costs

hotspot

Readout LOUD podcast, live from the STAT Breakthrough Summit East

A cyberattack has disrupted hospitals and health care in several states

Attacks on the drug industry will lead to fewer breakthroughs

Biotech investment managers search for lucrative opportunities

U.K. officials, researchers try to ease path for bespoke genetic treatments

Humana, CVS hope to turn members into patients at clinics

Wikipedia

hotspot

explore

focus